6CM
MDGL icon

683 Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

683 Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,865
Closed -$9.28M – 150
2025
Q2 		$7.53M Buy
24,865
+1,289
+5% +$384K 0.49% 55
2025
Q1 		$7.81M Buy
23,576
+22,576
+2,258% +$7.42M 0.54% 54
2024
Q4 		$309K Buy
+1,000
New +$281K 0.02% 204

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

683 Capital Management's MDGL Position: Q3 2025 in Review

683 Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2025, closing a stake of 24,865 shares — an estimated $9.28M sold.

683 Capital Management first reported a position in MDGL in Q4 2024 and held it in 3 quarters. The position peaked at $7.81M in Q1 2025. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

  • 683 Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • 683 Capital Management sold 24,865 Madrigal Pharmaceuticals shares in Q3 2025, an estimated $9.28M.
  • 683 Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • 683 Capital Management's Madrigal Pharmaceuticals position peaked at $7.81M in Q1 2025.
  • 352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on 683 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.